The findings of our translational study, aimed at improving both the selection of rectal cancer patients for WW and follow-up monitoring, indicate that primary-tumor-informed analysis of liquid biopsies can be used to measure disease burden and might be useful to monitor NAT efficacy, with the caveat of low specificity for detection of MRD and prediction of scCR. This evidence concerns the gene BRD2 and neoplasm.